IL37 and sarcopenia: Thus, as shown in Figure 4, to accurately validate circulating levels of IL-37 as a diagnostic tool in T2D patients, there is the need to recognize several MS phenotypes, relating them to the degree of frailty, sarcopenia, and categories of BMI.